David A. Siegel Protalix Bio Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 33,015 shares of PLX stock, worth $56,125. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,015Holding current value
$56,125% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding PLX
# of Institutions
69Shares Held
8.26MCall Options Held
227KPut Options Held
54.5K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$2.02 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny963KShares$1.64 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA859KShares$1.46 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$1.16 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0615KShares$1.05 Million0.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $84.6M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...